Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Exploratory, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline

NCT05199142 is registered in ClinicalTrials.gov with Syndesi Therapeutics as lead sponsor.

NCT NCT05199142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05199142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Exploratory, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline
Lead sponsor
Syndesi Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
September 23, 2021
Completion date
March 11, 2022
Enrollment
5 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive decline